Clinical Trials Logo
  1. Home
  2. Cutaneous T-Cell Lymphoma
  3. NCT05956041

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Cutaneous T Cell Lymphoma Clinical Trial

Official title:
A Phase II Study of Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Clinical Trial Summary

This is an open-label, single-arm, multicenter, phase II study combining pembrolizumab and mogamulizumab in patients with advanced-stage, relapsed or refractory CTCL Each cycle will equal 6 weeks. Pembrolizumab will be administered on Day 1 of each cycle. Mogamulizumab will be administered on Day 1, 8, 15, and 22 of Cycle 1. For Cycle 2 and subsequent cycles, mogamulizumab will be administered on Day 1, 15 and 29 of each cycle. Subjects will undergo a response assessment prior to Cycle 3 and every 2 cycles thereafter. Subjects will continue study treatment until documented progression, unacceptable toxicity, or any other condition for discontinuation is met in protocol. A maximum of 2 years of study treatment may be administered. If a subject achieves a complete response (CR) per mSWAT criteria after 3 months of study treatment (2 cycles), they will continue study therapy for an additional 6 months (4 cycles). If a confirmed and persistent CR is met, they may discontinue study treatment and enter an observation period in protocol. Repeat disease evaluation is required prior to study therapy discontinuation. Subjects who progress during the observation period may be eligible for up to an additional 9 cycles (1 year) of pembrolizumab and mogamulizumab.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05956041
Study type Interventional
Source University of Michigan Rogel Cancer Center
Contact Cancer AnswerLine
Phone 1-800-865-1125
Email CancerAnswerLine@med.umich.edu
Status Recruiting
Phase Phase 2
Start date December 6, 2023
Completion date December 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT02546440 - Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL) Phase 2
Recruiting NCT04014374 - Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
Recruiting NCT03340155 - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases N/A
Active, not recruiting NCT01460914 - Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment
Completed NCT04955340 - A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat Phase 1
Recruiting NCT02539472 - Early Diagnosis of Mycosis Fungoides N/A
Recruiting NCT06436677 - A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
Recruiting NCT05680558 - Photopheresis in Early-stage Mycosis Fungoides Phase 2
Recruiting NCT01132989 - Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma Phase 2
Recruiting NCT05414500 - Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides Phase 1
Terminated NCT01663571 - STAT3 in T Cells: At The Crossroads of Inflammation and Cancer
Active, not recruiting NCT02192021 - Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) Phase 1
Recruiting NCT05781386 - A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors Phase 1
Active, not recruiting NCT02576496 - Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Phase 1
Active, not recruiting NCT03775525 - Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer Phase 1
Withdrawn NCT03235869 - Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma Early Phase 1
Active, not recruiting NCT01396070 - Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level N/A
Completed NCT01198665 - RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas Phase 1/Phase 2
Recruiting NCT03932279 - Characterization of the Microbiome in Cutaneous T Cell Lymphoma
Not yet recruiting NCT05728879 - Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution Early Phase 1